Moberg Pharma AB (OSTO:MOB) Total Current Assets : kr347.86 Mil (As of Jun. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Moberg Pharma AB Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Moberg Pharma AB's total current assets for the quarter that ended in Jun. 2024 was kr347.86 Mil.

Moberg Pharma AB Total Current Assets Historical Data

The historical data trend for Moberg Pharma AB's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moberg Pharma AB Total Current Assets Chart

Moberg Pharma AB Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

211.95

104.66

127.76

69.49

Moberg Pharma AB Quarterly Data
	Jun19	Sep19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Total Current Assets	Get a 7-Day Free Trial															54.93	105.15	69.49	48.28	347.86

Moberg Pharma AB Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Moberg Pharma AB's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	59.855	+	0.786	+	7.115	+	1.737
	=	69.49

Moberg Pharma AB's Total Current Assets for the quarter that ended in Jun. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	325.958	+	16.945	+	4.952	+	0
	=	347.86

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Moberg Pharma AB (OSTO:MOB) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Moberg Pharma AB's Liquidation Value for the quarter that ended in Jun. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	325.958	-	30.544	+	0.75 * 16.945	+	0.5 * 4.952
=	310.60

Moberg Pharma AB Total Current Assets Related Terms

Thank you for viewing the detailed overview of Moberg Pharma AB's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Moberg Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Moberg Pharma AB (OSTO:MOB) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

MOBs:UK MB8:Germany

Address

Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51

Website

https://www.mobergpharma.se

Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Moberg Pharma has commercial agreements with partners in Europe and Canada, among others.